18Fluorodeoxyglucose pet is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 5, 2010, Pages 1420-1425

  Schellenberg, Devin ^a   Quon, Andy ^b   Minn, A Yuriko ^b   Graves, Edward E ^b   Kunz, Pamela ^b   Ford, James M ^b   Fisher, George A ^b   Goodman, Karyn A ^c   Koong, Albert C ^b   Chang, Daniel T ^b  

^a Fraser Valley Cancer Centre   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Locally advanced; Pancreas; PET; Survival

Indexed keywords

FLUORODEOXYGLUCOSE; GEMCITABINE; IN-HOUSE SOFTWARE; INDEPENDENT PREDICTORS; LOCALLY ADVANCED; MEDIAN SURVIVAL; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS; PANCREAS CANCER; PET; PET SCAN; PRE-TREATMENT; PROGRESSION FREE SURVIVAL; STANDARDIZED UPTAKE VALUES; STEREOTACTIC BODY RADIOTHERAPY; STEREOTACTIC RADIOTHERAPY; SURVIVAL;

CARBOHYDRATES; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DRUG PRODUCTS; MULTIVARIANT ANALYSIS; RADIOTHERAPY; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; HUMAN; OVERALL SURVIVAL; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; BLOOD; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREAS TUMOR; RADIATION DOSE; RADIOSURGERY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 77955477778     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.049     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
2. A. Brade, J. Brierley, and A. Oza Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A Phase I-II study Int J Radiat Oncol Biol Phys 67 2007 1027 1036
3. Treatment of locally unresectable carcinoma of the pancreas Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group J Natl Cancer Inst 80 1988 751 755
4. Eastern Cooperative Oncology Group. ECOG-4201: Phase III randomised study of gemcitabine with or without radiotherapy in patients with locally advanced, unresectable pancreatic cancer. 2008.
5. C.G. Moertel, S. Frytak, and R.G. Hahn Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1981 1705 1710
6. D. Yip, C. Karapetis, and A. Strickland Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Cochrane Database Syst Rev 3 2006 CD002093
7. A.C. Koong, E. Christofferson, and Q.T. Le Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 63 2005 320 323
8. A.C. Koong, Q.T. Le, and A. Ho Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 58 2004 1017 1021
9. D. Schellenberg, K.A. Goodman, and F. Lee Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 72 2008 678 686
10. P. Lee, D.K. Weerasuriya, and P.W. Lavori Metabolic tumor burden predicts for disease progression and death in lung cancer Int J Radiat Oncol Biol Phys 69 2007 328 333
11. S.W. Lee, S.Y. Nam, and K.C. Im Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas Radiother Oncol 87 2008 211 216
12. D.T. Chang, D. Schellenberg, and J. Shen Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas Cancer 115 2009 665 672
13. E.E. Graves, A. Quon, and B.W. Loo Jr. RT-Image: An open-source tool for investigating PET in radiation oncology Technol Cancer Res Treat 6 2007 111 121
14. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. C.R. Ferrone, D.M. Finkelstein, and S.P. Thayer Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol 24 2006 2897 2902
16. A.C. Berger, M. Garcia Jr., and J.P. Hoffman Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 J Clin Oncol 26 2008 5918 5922
17. E.D. Saad, M.C. Machado, and D. Wajsbrot Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine Int J Gastrointest Cancer 32 2002 35 41
18. S. Krishnan, V. Rana, and N.A. Janjan Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation Cancer 107 2006 2589 2596
19. C. Ziske, C. Schlie, and M. Gorschluter Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine Br J Cancer 89 2003 1413 1417
20. D. Wong, A.H. Ko, and J. Hwang Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy Pancreas 37 2008 269 274
21. V. Hess, B. Glimelius, and P. Grawe CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial Lancet Oncol 9 2008 132 138
22. H.L. Kindler, D. Niedzwiecki, and D. Hollis A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). 2007 ASCO Annual Meeting J Clin Oncol 25 2007 4508
23. V. Heinemann, D. Quietzsch, and F. Gieseler Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 2006 3946 3952
24. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403 2413
25. P.A. Philip, J. Benedetti, and C. Fenoglio-Preiser Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study, 2007 ASCO Annual Meeting J Clin Oncol 25 2007 4509
26. C.M. Rocha Lima, M.R. Green, and R. Rotche Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
27. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1996
28. M. Hockel, K. Schlenger, and B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
29. V. Rudat, B. Vanselow, and P. Wollensack Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer Radiother Oncol 57 2000 31 37